Additional Data on Provectus’s PV-10 for Metastatic Melanoma Presented at Prominent Melanoma Conferences
Additional Data on Provectus’s PV-10 for Metastatic Melanoma Presented at Prominent Melanoma Conferences
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals announced that data and study design features on PV-10 for metastatic melanoma were presented at two separate conferences.
Read more on Business Wire
Categories: Breast Cancer Information Tags: Additional, Conferences, Data, Melanoma, Metastatic, presented, Prominent, Provectus’s, PV10
Connection between light at night and cancer revealed in additional study
Connection between light at night and cancer revealed in additional study
( University of Haifa ) The researchers say that their study results show that suppression of melatonin due to exposure to light at night, or LAN, is linked to the worrying rise in the number of cancer patients over the past few years.
Read more on EurekAlert!
Categories: Breast Cancer Organizations Tags: Additional, Between, cancer, connection, light, night, Revealed, Study
Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive metastatic breast cancer
Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive metastatic breast cancer
Incyte Corporation announced today additional positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 66 patients with HER2-positive metastatic breast cancer during a poster session at the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL, June 4 to June 8, 2010.
Read more on News-Medical-Net
Categories: Breast Cancer Pain Tags: Additional, breast, cancer, From, HER2positive, I/II, INCB7839, Incyte, Metastatic, Phase, presents, Results, Trial
GTx Presents Additional Results In Quality Of Life Improvements From The Phase IIb Evaluating Ostarine™ For Cancer …
GTx Presents Additional Results In Quality Of Life Improvements From The Phase IIb Evaluating Ostarine™ For Cancer …
GTx, Inc. (Nasdaq: GTXI) presented additional results from the Ostarine™ Phase IIb study demonstrating an improvement in quality of life (fatigue and anorexia) in cancer patients with muscle wasting (cancer cachexia) who demonstrated improvement in functional performance as measured by stair climb. Ostarine (GTx-024) is GTx’s lead selective androgen receptor modulator (SARM) which the company is …
Read more on Medical News Today
Categories: Breast Cancer Chemotherapy Tags: Additional, cancer, evaluating, From, Improvements, Life, Ostarine™, Phase, presents, Quality, Results